By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting out of Paris, France, by NewsRx editors, research stated, "Sunitinib is an inhibitor of tyrosine-kinase receptors, and no biomarker predictive of sunitinib response is available. The purpose of this preclinical study was to show whether sunitinib molecular targets could be used as biomarkers to assess tumor response to sunitinib in human cancer cell line xenografts of three different tumor types."
Our news journalists obtained a quote from the research from the University of Paris, "Using mice xenografted with liver, breast and renal carcinoma cell lines, we sequentially analyzed the effect of 7-day sunitinib treatment on tumor and vascular compartments. In all xenografts, microvessel damage occurred from Day 1. Tumor damage also occurred in liver, breast, but not in renal xenografts. Using specific human and mouse probes for genes encoding sunitinib targets, we showed a significant relation between apoptotic tumor cell numbers and human PDGFRI' and RET mRNA expression in liver cancer and to human VEGFR2 expression in breast cancer xenografts. In contrast, in renal cancer xenografts, vascular effect evaluated by measuring endothelial cell apoptosis was related to mouse Vegfr1, Vegfr2 and Vegfa-164 expression."
According to the news editors, the research concluded: "This study identifies sunitinib vascular and tumor effects according to different tumor types and shows that sunitinib molecular targets used as biomarkers enable assessment of therapeutic response."
For more information on this research see: Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. Cancer Chemotherapy and Pharmacology, 2013;72(6):1183-1193. Cancer Chemotherapy and Pharmacology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Cancer Chemotherapy and Pharmacology - www.springerlink.com/content/0344-5704/)
Our news journalists report that additional information may be obtained by contacting G. Bousquet, University of Paris, Hopital St Louis, INSERM, UMR S728Lab Pathol, F-75010 Paris, France. Additional authors for this research include M. Varna, I. Ferreira, L. Wang, P. Mongiat-Artus, C. Leboeuf, C. de Bazelaire, S. Faivre, P. Bertheau, E. Raymond, S. Germain and A. Janin (see also Biotechnology).
Keywords for this news article include: Antineoplastics, Biotechnology, Paris, Drugs, France, Europe, Kidney, Genetics, Oncology, Apoptosis, Sunitinib, Xenograft, Nephrology, Therapeutics, Xenotransplantion, Cancer Gene Therapy, Multikinase Inhibitors, VEGF - VEGFR Inhibitors, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC